P. B.S. Clarke, “Nicotinic Receptor Blockade Therapy and Smoking Cessation”, British Journal of Addiction, 1991, vol. 86, pp. 501-505. |
T. Eissenberg et al., “Mecamylamine Does Not Precipitate Withdrawal in Cigarette Smokers”, Psychopharmacology, 1996, vol. 127, pp. 328-336. |
L. H. Ferry, MD, MPH et al., “Efficacy of Bupropion for Smoking Cessation in Non Depressed Smokers”, Journal of Addictive Diseases, 1994, vol. 13, p. 249. |
E. D. Freis, MD et al., “Mecamylamine, a New, Orally Effective, Hypotensive Agent”, Archives of Internal Medicine, 1956, vol. 97, pp. 551-561. |
J. E. Henningfield, Ph.D., “Pharmacologic Basis and Treatment of Cigarette Smoking”, Journal of Clinical Psychiatry, Dec. 1984, vol. 45:12 (Sec. 2), pp. 24-34. |
J. E. Henningfield et al., “Nicotine Medications for Smoking Cessation”, The New England Journal of Medicine, Nov. 2, 1995, vol. 333, No. 18, pp. 1196-1203. |
J. E. Henningfield et al., “Progress in Understanding the Relationship Between the Pharmacological Effects of Nicotine and Human Tobacco Dependence”, Pharmacology Biochemistry & Behavior, vol. 30, 1988 pp. 217-220. |
J. R. Hughes, “Pharmacology for Smoking Cessation: Unvalidated Assumptions, Anomalies, and Suggestions for Future Research”, Journal of Consulting and Clinical Psychology, 1993, vol. 61, No. 5, pp. 751-760. |
J. R. Hughes, Non-Nicotine Pharmacotherapies for Smoking Cessation, J. Drug Development, 1994, vol. 6, No. 4, pp. 197-203. |
R. D. Hurt, MD et al., “A Comparison of Sustained Release Bupropion and Placebo for Smoking Cessation”, The New England Journal at Medicine, Oct. 23, 1997, vol. 337, pp. 1195-1202. |
M. E. Jarvik et al., “Pharmacological Treatment of Tobacco Dependence”, Pharmacology Biochemistry & Behavior, 1988, vol. 30, pp. 279-294. |
R. M. Keenan, MD et al., “Management of Nicotine Dependence and Withdrawal”, in Miller, N.S. (ed.), Principles of Addiction Medicine, Chevy Chase, Maryland, American Society of Addiction Medicine, 1994, pp. 1-13. |
D. H. Malin et al., “The Nicotinic Antagonist Mecamylamine Precipitates Nicotine Abstinence Syndrome in the Rat”, Psychopharmacology, 1994, vol. 115, pp. 180-184. |
B. R. Martin et al., “What is the Nature of Mecamylamine's Antagonism of the Central Effects of Nicotine?” Biochemical Pharmacology, 1989, vol. 38, No. 20, pp. 3391-3397. |
P. A. Newhouse et al., “Acute Nicotinic Blockade Produces Cognitive Impairment in Normal Humans”, Psychopharmacology, 1992, vol. 108, pp. 480-484. |
P. A. Newhouse et al., “Age-Related Effects of the Nicotinic Antagonist Mecamylamine on Cognition and Behavior”, Neuropsychopharmacology, 1994, vol. 10, No. 2, pp. 93-107. |
R. Nemeth-Coslett et al., “Effects of Mecamylamine on Human Cigarette Smoking and Subjective Ratings”, Psychopharmacology, 1986, vol. 88, pp. 420-425. |
C. L. Nunn-Thompson et al., “Pharmacotherapy for Smoking Cessation,” Clinical Pharmacy, Oct. 1989, vol. 8, No. 10, pp. 710-720. |
W. B. Pickworth et al., “Mecamylamine Reduces Some EEG Effects of Nicotine Chewing Gum in Humans”, Pharmacology Biochemistry & Behavior, 1988, vol. 30, pp. 149-153. |
W. B. Pickworth et al., “Effects of Mecamylamine on Spontaneous EEG and Performance in Smokers and Non-Smokers”, Pharmacology Biochemistry and Behavior, 1997, vol. 56, No. 2, pp. 181-187. |
C. S. Pomerleau et al., “Mecamylamine Pretreatment Increases Subsequent Nicotine Self-Administration as Indicated by Changes in Plasma Nicotine Level”, Psychopharmacology, 1987, vol. 91, pp. 391-393. |
J. Prignot, “Pharmacological Approach to Smoking Cessation”, Eur. Respir. Journal, 1989, vol. 2, pp. 550-560. |
J. E. Rose, Ph.D., “Nicotine Addiction and Treatment,” Annual Review of Medicine, 1996, vol. 47, pp. 493-507. |
J. E. Rose et al., “Mecamylamine Increases Nicotine Preference and Attenuates Nicotine Discrimination”, Pharmacology Biochemistry & Behavior, 1989, vol. 32, pp. 933-938. |
J. E. Rose, Ph.D. et al., “Mecamylamine Combined with Nicotine Skin Patch Facilitates Smoking Cessation Beyond Nicotine Patch Treatment Alone”, Clinical Pharmacology & Therapeutics, Jul. 1994, pp. 86-99. |
J. E. Rose et al., “Nicotine/Mecamylamine Combination Treatment for Smoking Cessation”, Drug Development Research, 1996, vol. 38, pp. 243-256. |
J. A. Rosecrans et al., “Mecamylamine vs. Nicotine Tolerance”, Journal of Addictive Diseases, 1994, vol. 13, p. 248. |
D. P.L. Sachs, MD et al., “Pharmacologic Approaches to Smoking Cessation”, Clinics in Chest Medicine, 1991, vol. 12, No. 4, pp. 769-791. |
I. P. Stolerman, “Could Nicotine Antagonists be Used in Smoking Cessation?” British Journal of Addiction, 1986, vol. 81, pp. 47-53. |
I. P. Stolerman et al., “Influencing Cigarette Smoking with Nicotine Antagonists”, Psychopharmacologia (Berl.), 1973, vol. 28, pp. 247-259. |
F. S. Tennant, Jr. et al., “Clinical Evaluation of Mecamylamine for Withdrawal from Nicotine Dependence”, NIDA Monograph, 1984, vol. 49, pp. 239-246. |
F. S. Tennant, Jr. et al., “Withdrawal from Nicotine Dependence Using Mecamylamine: Comparison of Three-Week and Six-Week Dosage Schedules”, NIDA Monograph, 1985, vol. 55, pp. 291-297. |
D. P. Yells et al., “Monoaminergic Influences on Tmeporal Patterning of Sexual Behavior in Male Rats,” Physiology & Behavior, 1995, vol 58, No. 5, pp. 847-852. |